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Idiopathicpulmonaryﬁbrosis(IPF)ischaracterized by slowlyprogressiverespiratorydysfunction. Nevertheless,someIPFpatients
experience acute exacerbations generally characterized by suddenly worseningand fatalrespiratory failure withnew lung opacities
andpathologicallesionsofdiﬀuse alveolardamage.Acute exacerbation ofidiopathicpulmonaryﬁbrosis(AEIPF) isa fataldisorder
deﬁned by rapid deterioration of IPF. The condition sometimes occurs in patients who underwent lung resection forprimary lung
cancer in the acute and subacute postoperative phases. The exact etiology and pathogenesis remain unknown, but the condition
is characterized by diﬀuse alveolar damage superimposed on a background of IPF that probably occurs as a result of a massive
lung injury due to some unknown factors. This systematic review shows that the outcome, however, is poor, with postoperative
mortalityranging from 33.3% to 100%. In this paper, the etiology, risk factors, pathogenesis,therapy, prognosis,and predictors of
postoperative AEIPF are described.
1.IntroductionandBackground
The incidence of lung cancer in patients with idiopathic
pulmonary ﬁbrosis (IPF) is higher than the general popu-
lation, with relative risks reported to be from 7 to 14% [1–3]
IPF is usually a gradually progressive but an ultimately fatal
disease. Although the disease is chronic in nature, abrupt
worsening can occur in some patients. This condition was
ﬁrst introduced by Kondoh and Saiki [4]a n dw a st h e n
called acute exacerbation of IPF (AEIPF). The prognosis
of AEIPF is usually considered to be grave, but it has been
reported that some patients show improvement following
corticosteroid therapy. It still remains uncertain what causes
such an acute exacerbation, and appropriate therapy for
this condition has not been established. In the survey
by the Japanese association of thoracic surgery, 1036 of
27881 patients who underwent pulmonary resection for
primary lung cancer during the year 2008 had interstitial
pneumonia as a preoperative comorbidity. Although the
hospital mortality was about 0.9% (248 patients died after
the operation), 63 of 248 patients (25.4%) died of interstitial
pneumonia, including AEIP. We are focused on the current
knowledge of AEIPF and what causes the exacerbation after
pulmonary resection for nonsmall celllungcancer (NSCLC).
2.The Content
2.1. Diagnostic Criteria for Acute Exacerbation of IPF. The
acute exacerbation of IPF (AEIPF) is characterized by diﬀuse
and rapid alveolar damage superimposed on a background
of IPF that probably occurs as a result of a massive lung
injury due to some unknown etiologic agent. The deﬁnition
of AEIPF was ﬁrst described by Yoshimura et al. [5]. The
characteristics include (1) intensiﬁed dyspnea, (2) increase
in the interstitial shadow on chest radiograph, (3)increase in
ﬁne crackles on auscultation, (4) elevation of serum lactate
dehydrogenase, and (5) decrease in arterial oxygen tension
of more than 10 mm Hg under similar condition. After then,
some diagnostic criteria have been described [6–11]. In the
clinical ﬁeld and the surgical ﬁeld, the deﬁnition described
by Hyzy has been generally applied (Table 1).2 Pulmonary Medicine
Table 1: Deﬁnition of acute exacerbation of IPF described by Hyzy
et al. [10].
Previous or concurrent diagnosis of IPF∗
Unexplained worsening or development of dyspnea within 30d
High-resolution CT scan with new bilateral ground-glass
abnormality and/or consolidationsuperimposed on a
background reticular or honeycomb pattern consistent with a
UIP pattern†
Worsening hypoxemia from a knownbaseline arterial blood
gas‡
No evidence of pulmonary infection by endotracheal aspiration
or BAL
Exclusion of alternative causes, including
left heart failure
pulmonary embolism
identiﬁable cause of acute lung injury§
∗This criterion can be met by the presence of radiologic and/or histopatho-
logicchanges consistentwithaUIPpattern ifadiagnosisof IPFhas not been
previously established by American Thoracic Society/European Respiratory
Society criteria.
†Current high-resolution CT scan is acceptable without prior high-
resolution CT scan for comparison if none is available.
‡Includes evaluation for common bacterial organisms and viral pathogens.
§Causes of lung injury include sepsis, aspiration, trauma, transfusion of
blood products, pulmonarycontusion, fatembolization,drug toxicity,acute
pancreatitis, inhalational injury, and cardiopulmonary bypass.
Especially, bacterial pneumonia must be distinguished
from AEIPF. Pneumonia is diagnosed by the presence
of new and/or progressive pulmonary inﬁltrates on chest
radiography plus two or more of the following criteria:
fever (38◦C), leukocytosis(12×109/L), purulent sputum, or
isolation of pathogen in respiratory secretions. If necessary,
endotracheal aspiration or BA is performed.
2.2. Etiology. Speciﬁc factors causing AEIPF have not been
elucidated. However, some cases of AEIPF have occurred
after lung resection or biopsy [13, 21]. Kondoh et al. [22]
observed that postbiopsy exacerbation occurred in 2.1% of
236 consecutive patients who underwent surgical biopsy for
diﬀuse lung disease. AEIPF appear to occur at any time
during the course of disease and may be the presenting
manifestation for some patients. Importantly, the risk of an
exacerbation does not appear to be linked to the level of
pulmonary function [23];althoughinoneprospective series,
patients with lower forced vital capacity had more total
and respiratory-related hospitalizations during subsequent
followup [24]. There is no clear association with age or
smoking history, but acute exacerbations seem to be more
c o m m o ni nm e n .
2.3. Pathology. AEIPF is an acute insult to the lung over a
background of IPF. According to some autopsy studies [25–
27], there was a wide distribution in the extent of ﬁbroblastic
foci but not seen in ﬁbrotic nonspeciﬁc interstitial pneumo-
nia. Fibroblastic foci were distinguished from buds of intra-
alveolar organization seen in the organizing phase of diﬀuse
alveolar damage by their immediate adjacency to areas of
established ﬁbrosis and their presence away from areas of
established diﬀuse alveolar damage. Areas showing honey-
comb changes contained aggregates of abundant neutrophils
within the air spaces; however, staining for organisms was
uniformly negative in these areas and the results for tissue
taken for culture at autopsy also were negative.
2.4. Incidence and Mortality of Postoperative AEIPF. Accord-
ing to the annual report by the Japanese association of
thoracic surgery [28], 1036 of 27881 patients (3.7%) who
underwent pulmonary resection for primary lung cancer
during the year 2008 had interstitial pneumonia as a preop-
erative comorbidity. Although the whole hospital mortality
was about 0.9% (248 patients died after the operation), 63
patients (25.4%) died of interstitial pneumonia, including
AEIPF. Additionally, 157 patients suﬀered from AEIPF
during hospitalization.
Six (15.0%) of 40 patients with IPF had AEIPF after the
operation and 5 of the six died with respiratory failure at
POD 47 on average (range 17–95 days) [20]. We reported
that 4 (7.1%) of these 56 patients developed postoperative
AEIPF, and all of them died of respiratory failure within
42 days after the operation despite immunosuppression
with pulse doses of methylprednisolone [18]. The rate of
occurrence and mortality of postoperative AEIPF in the
literatures [12, 14, 16, 17] are summarized in Table 2.
The incidence of postoperative AEIPF ranged from 0%
to 20.8%, mortality after pulmonary resection from 8.3%
to 22.9%, and mortality after occurrence of AEIPF from
37.5% to 100%. On the other hand, AEIPF may occur
after any medical treatment for cancer. Minegishi et al.
reportedthattheincidenceandmortalityaftereachanti-lung
cancer therapy, including pulmonary resection, were 20%
and 14% for chemotherapy (n = 50), 42.9% and 14.3% for
chemoradiotherapy (n = 7), 16.7% and 16.7% for radiation
therapy (n = 6), 22.9% and 8.9% for pulmonary resection
(n = 35), and 31.3% and 31.3% for best supportive care
(n = 32) [19], respectively.
2.5. Risks of Postoperative Exacerbation of IPF. Kumar et
al. [13] reported that postoperative ARDS was associated
with lower preoperative levels of carbon monoxide diﬀusion
capacity corrected for alveolar volume (KCO), lower pre-
operative DLCO levels, and higher preoperative composite
physiological index [29]( C P I= 91.0 − (0.65 × %p r e d i c t e d
DLCO) − (0.53 × % predicted FVC) + (0.34 × %p r e d i c t e d
FEV1)). A preoperative CPI score >40 was associated with
a 50% chance of developing postoperative lung injury. The
occurrence of ARDS was not related to demographic fea-
tures, smoking history, other pulmonary function variables,
presence of preoperative dyspnea, histologically established
diagnosis of pulmonary ﬁbrosis before pulmonary resection,
stage of nonsmall cell lung cancer, or pattern of inﬂamma-
tion.
% vital capacity (VC) (<80.6%) and LDH level
(≥241IU/L) achieved a complete classiﬁcation of patients
with AEIPF from those without AEIPF [28]. The other
researchers reported that postoperative AEIPwere associatedPulmonary Medicine 3
Table 2: The incidence and mortality of postoperative acute exacerbation of IPF.
Author Published
year
No. of
AEIPF
Incidence of
AEIPF (%)
Death of
AEIPF Mortality Mortality
after AEIPF
No. of IPF
Pts
Total no. of
Pts
Fujimoto et al. [12] 2003 0 0 0 0 NA 21 NA
Kumar et al. [13] 2003 5 (ARDS) 20.8 4 16.7 80 24 988
Chiyo et al. [14] 2003 9 25 3 8.3 33.3 36 931
Koizumi et al. [15] 2004 7 14.9 6 12.8 85.7 47 1103
Okamoto et al. [16] 2004 4 20 3 20 75 20 NA
Kushibe et al. [17] 2007 4 12.1 4 18.2 100 33 1066
Watanabe et al. [18] 2008 4 7.4 4 7.4 100 54 870
Minegishi et al. [19] 2009 8 8.6 3 22.9 37.5 35 NA
Shintani et al. [20] 2010 6 15 5 12.5 83.3 40 1256
AEIPF: acute exacerbation of idiopathic pulmonary ﬁbrosis, NA: not available, Pts: patients, ARDS: acute respiratory distress syndrome.
with %VC < 80% [16, 17], low DLCO [16], and %TLC <
95% [29].
The incidence of postoperative complications associated
with video-assisted thoracoscopic surgery (VATS) seemed to
be low although the use of VATS could not prevent AE of
usual interstitial pneumonia (UIP) [15].
On the other hand, our study demonstrated no observed
predictive risks of postoperative AEIPF after lung resection
forprimary lungcancer[18].Therisks,whicharereportedin
the literatures, are shown on Table 3.H o w e v e r ,t h e s er e p o r t s
are from the study of a single institution and the number
of patients is too small for statistical analysis of the risks.
The aforementioned pose as limitations of the study. In the
Japanese association of chest surgery, a multi-institutional
Study of the postoperative exacerbation of IPF is currently
being conducted.
2.6. Strategy for Decreasing the Incidence of Postoperative
AEIPF. Surgical approaches, such as conventional thora-
cotomy, muscle sparing thoracotomy, and video-assisted
thoracoscopic surgery have no eﬀect on the occurrence
of postoperative AEIPF [30]. Some unknown or potential
etiologic agents of AEIPF must be induced by pulmonary
resection or some factors related to pulmonary resection,
such as selective lung ventilation and manipulation of the
ipsilateral lung. If oxygenradical toxicitycan be associated to
theoccurrenceofAEIPF,Misthosetal.[31]recentlyreported
this interesting theory. The authors revealed the following
results: (1) lung re-expansion after one-lung ventilation
(OLV) provoked severe oxidative stress; (2) the degree of
generated oxygen-derived free radicals was associated with
the duration of OLV; (3) patients with lung cancer had a
higher production of oxygen-derived free radicals than the
normal population; (4) tumor resection removes a large
oxidative burden from the organism; (5) mechanical venti-
lation and surgical trauma are weak free radical generators;
(6) manipulated lung tissue is also a source of oxygen-
derived free radicals, not only intraoperatively but also for
several hours later. These results indicate that shortening the
duration of OLV and avoiding manipulation of lung tissue
may inhibit the occurrence of AEIPF resulting from oxygen-
derived free radicals.
Nodrughas beenestablished todecrease the incidenceof
AEIPF. Few studies reported that steroid, pirfenidone [32],
and anticoagulants [33] reduce the occurrence of AEIPF in
patients with IPF. However, regarding postoperative AEIPF,
so far, no researchers presented a drug that can prevent
or decrease the occurrence of postoperative AEIPF. Thus,
thoracic surgeons use some drugs reported to reduce the
incidence of AEIPF or slow the deterioration of IPF, such
as macrolides [34, 35], N-acetylcysteine [36–39], proteinase
inhibitor [40, 41], and pirfenidone [42, 43]. The eﬀect of
these drugs on decreasing the incidence of postoperative
AEIPF remains unclear; therefore, multi-institutional ran-
domized controlled study should be planned in order to
determine the eﬀect of these drugs.
2.7. Treatment of Postoperative AEIPF. In the absence of
any eﬀective therapeutic regimens, postoperative AEIPF
seems to be a fatal problem. Although most patients with
nonpostoperative AEIPF have been treated with regimens
that includehigh-dose corticosteroids [44], the vast majority
shows only partial and temporary improvement. In post-
operative AEIPF, the situation is similar. Some investigators
have even suggested that mechanical ventilation does not
beneﬁt IPF patients presenting with acute respiratory failure
[45]. Yokoyama and associates [46] suggest that noninvasive
ventilation can be a possible option for the management of
acute respiratory failure in patients with AEIPF.
Some studies reported that immunosuppressive agents,
such as Cyclosporine A [47–49] and cyclophosphamide[50],
improve the prognosis of AEIPF. However, Okamoto et
al. [16] reported that patients with AEIPF under methyl-
prednisolone pulse therapy in combination with cyclophos-
phamide or cyclosporine A did not signiﬁcantly improve
the outcome of AEIPF. In conclusion, there is little evidence
that currently accepted treatments are eﬀective in AEIPF,
and further studies are needed to clarify the pathogenesis
and contribute to the prevention of AEIPF. On the other
hand, there are some reports on the eﬀect of hemoperfusion
[51, 52] on AEIPF. The study by Seo et al. showed that six
patients with AEIPF underwent polymyxin B-immobilized
ﬁber column (PMX) hemoperfusion treatment. In four of4 Pulmonary Medicine
Table 3: The risk predictors of the postoperative acute exacerbation.
Author Published year Risk predictors of postoperative AEIPF
Kumar et al. [13] 2003 Low %DLco (AEIPF+ versus AEIPF−; 48% versus 58%), Low %KCO (58% versus
70%), High CPI (44 versus 33)
Koizumi et al. [15] 2004 PS > 2, CRP > 2mg/dL,LDH> 400IU/L,%TLC < 95%
Okamoto et al. [16] 2004 %VC < 80, LowDLco (value is not described)
Kushibe et al. [17] 2007 %VC < 80%
Watanabe et al. [18] 2008 None
Shintani et al. [20] 2010 %VC (<80.6%) and LDH (≥241IU/L)
KCO: levels of carbon monoxide diﬀusion capacitycorrected for alveolar volume;
CPI: composite physiological index; PS: performance status; TLC: total lung capacity;
DLCO: diﬀusing capacityof the lung for carbon monoxide.
six patients, alveolar-arterial diﬀerence ofoxygen,serumKL-
6, and lactate dehydrogenase level were improved after PMX
treatment. These four patients were successfully weaned
from mechanical ventilation and survived more than 30
days after the initial PMX treatment. However, this study
involved a small number of patients and/or the absence of
randomization. A randomized controlled study will be more
factual.
3.Conclusionand FutureDirections
AEIPF frequently occurs after lung resection for lung cancer
with fatal outcome. Nowadays, there is no deﬁnitive treat-
ment guidelines and eﬀective prevention on the occurrence
of AEIPF. A randomized study with statistically adequate
number of patients is required to identify the etiology, risk
factors, prognostic markers, and eﬀective treatments.
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